Olparib (Same as Lynparza)

Overview

Olaparib, marketed under the brand name Lynparza, is a targeted therapy used in the treatment of certain types of cancer, particularly those associated with BRCA mutations. It is classified as a PARP inhibitor, which works by interfering with the cancer cell's ability to repair its DNA, leading to cell death.

Benefits

• Effective in treating ovarian and breast cancers with BRCA mutations.
• Can be used as a maintenance therapy to prolong remission.
• Oral administration provides convenience for patients.
• May improve overall survival rates in specific patient populations.

Dosage

The typical dosage of Olaparib is 300 mg taken twice daily. It is important to follow the prescribing physician's instructions and to not exceed the recommended dose. Dosage may vary based on individual patient factors and specific cancer types.

Side Effects

Common side effects of Olaparib may include:

• Nausea
• Fatigue
• Vomiting
• Diarrhea
• Loss of appetite
• Anemia

Patients should report any severe or persistent side effects to their healthcare provider.

FAQs

Is Olaparib suitable for all cancer patients?

Olaparib is specifically indicated for patients with certain types of cancer that have BRCA mutations. It is not suitable for all cancer types.

How should Olaparib be taken?

Olaparib should be taken orally, with or without food. It is important to take it at the same time each day to maintain consistent levels in the body.

Can Olaparib be taken with other medications?

Patients should inform their healthcare provider of all medications they are taking, as some drugs may interact with Olaparib.